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DGCR6 at the proximal part of the DiGeorge critical region is
involved in conotruncal heart defects
Wenming Gao1, Takashi Higaki1, Minenori Eguchi-Ishimae1, Hidehiko Iwabuki1, Zhouying Wu1, Eiichi Yamamoto2, Hidemi Takata1,
Masaaki Ohta1, Issei Imoto3, Eiichi Ishii1 and Mariko Eguchi1
Cardiac anomaly is one of the hallmarks of DiGeorge syndrome (DGS), observed in approximately 80% of patients. It often shows a
characteristic morphology, termed as conotruncal heart defects. In many cases showing only the conotruncal heart defect, deletion
of 22q11.2 region cannot be detected by ﬂuorescence in situ hybridization (FISH), which is used to detect deletion in DGS. We
investigated the presence of genomic aberrations in six patients with congenital conotruncal heart defects, who show no deletion
at 22q11.2 in an initial screening by FISH. In these patients, no abnormalities were identiﬁed in the coding region of the TBX1 gene,
one of the key genes responsible for the phenotype of DGS. However, when copy number alteration was analyzed by
high-resolution array analysis, a small deletion or duplication in the proximal end of DiGeorge critical region was detected in two
patients. The affected region contains the DGCR6 and PRODH genes. DGCR6 has been reported to affect the expression of the TBX1
gene. Our results suggest that altered dosage of gene(s) other than TBX1, possibly DGCR6, may also be responsible for the
development of conotruncal heart defects observed in patients with DGS and, in particular, in those with stand-alone conotruncal
heart defects.
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INTRODUCTION
Cardiac anomaly is one of the congenital abnormalities frequently
observed in children, and some of them are known to be related
to genetic abnormalities such as chromosome aberrations. The
speciﬁc morphology of the cardiac anomaly often depends on the
underlying genetic change. One of the syndromes that frequently
includes a characteristic cardiac anomaly is DiGeorge syndrome
(DGS), also known as 22q11.2 deletion syndrome or velo-cardio-
facial syndrome.1–3
DGS is one of the most common microdeletion syndromes, with
a frequency of around 1 in 4000 to 6000 live births.4 Typical
symptoms include multiple developmental anomalies such as
cardiovascular malformations, palatal abnormalities, as well as
characteristic facial appearance, immunodeﬁciency, endocrine
dysfunction, hypocalcemia and intellectual disability. The types
of cardiac defects seen in DGS include tetralogy of Fallot,
pulmonary atresia, truncus arteriosus, interrupted aortic arch, type
B, and ventricular septal defect.2,3 Referred to as conotruncal heart
defects, the morphology of these cardiac anomalies is often
characteristic of DGS and frequently involves cardiac outﬂow tract
abnormality. As patients with 22q11.2 deletion may not always
have all the characteristic features of the syndrome, cases that are
found by chance are often initially suspected due to the presence
of the characteristic heart defect involving the outﬂow tract, and
are then screened for 22q11.2 deletion by ﬂuorescence in situ
hybridization (FISH) or other methods for a diagnosis of the
syndrome.
The chromosome 22q11.2 region contains several low copy
repeat (LCR) sequences that mediate non-allelic homologous
recombination and may cause copy number abnormalities.5
There are eight sets of LCRs, termed LCR A to H, and because
these LCRs share high homology with each other, the wrong LCRs
can align inappropriately during recombination events, leading to
a deletion on one resultant recombinant chromosome and a
duplication on the other within the 22q11.2 region.6–9 Approxi-
mately 90% of patients with DGS have a hemizygous 3-Mb
deletion at the 22q11.2 region (LCR-A to LCR-D, also called the
DiGeorge critical region) and 7% have a hemizygous 1.5-Mb
deletion (LCR-A to LCR-B). The remaining 3% of patients show less
common genomic alterations such as the deletion of a shorter
region.10 Although the distal breakpoint in the 22q11.2 deletion
can be variable, the majority of patients (97–98%) have a proximal
breakpoint within LCR-A.11
The DiGeorge critical region contains approximately 40 genes
within a 3-Mb region and 30 genes within a proximal 1.5-Mb
region.12 Identiﬁcation of the causative gene(s) within the deleted
region has been intensively investigated to elucidate the etiology
of the syndrome.
So far, haploinsufﬁciency of two genes, TBX113 and CRKL,14 in
the DiGeorge critical region on chromosome 22q11.2 have been
identiﬁed as causing the dysfunction of the neural crest cells
and anterior heart ﬁeld, two possible affected regions in the
morphogenesis of the syndrome.15,16 Although located distally
to the DiGeorge critical region on 22q11.2, haploinsufﬁciency
of MAPK1 (ERK2)17 and HIC218 also have been implicated as
contributors to the phenotype of DGS. These genes, with the
exception of HIC2, are considered to be essential for neural crest
cell development owing to their important roles in FGF8
(Fibroblast growth factor 8) signaling. Although the FGF8 gene is
not located within the 22q11.2 region, FGF8 inactivation can also
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produce the typical phenotype of DGS, including cardiac
malformations of the outﬂow tract and great vessels.19
TBX1 belongs to an evolutionarily conserved T-box family of
transcription factors whose expression is precisely regulated
during embryogenesis, and it appears to regulate the proliferation
and differentiation of various progenitor cells during
organogenesis.20 Importantly, an animal model indicated that
haploinsufﬁciency of the TBX1 gene could be responsible for
congenital heart defects, including cardiac outﬂow tract anomalies
similar to that observed in patients with DGS.21 In addition,
complete loss of TBX1 in mice resulted in a wide range of
developmental anomalies encompassing almost all of the
common DGS/velo-cardio-facial syndrome features, indicating a
dependence of these clinical phenotypes on TBX1 gene dosage.21
Although these genes were reported to be responsible for the
phenotype of DGS, several other genes were also identiﬁed in the
DiGeorge critical region, named as DGCR genes, and some of
them are also possible candidates for DGS phenotype. There are
14 DGCR genes located within this region and eight of them, such
as DGCR1, DGCR2, DGCR3, DGCR6, DGCR6L, DGCR8, DGCR14 and
DGCR15(FAM230A), are protein-coding genes.
Within these genes, some are known to be associated with the
clinical phenotype of the DGS. DGCR1, also known as HIRA or
TUPLE1, encodes a histone chaperone, and its haploinsufﬁciency
was considered to contribute to at least some of the features of
the DGS phenotype.22 DGCR6 encodes a nuclear phosphoprotein,
and in a chicken model, suppression of DGCR6 resulted in a high
incidence of cardiovascular anomalies reminiscent of those found
in DGS.23 DGCR8 encodes a subunit of the microprocessor
complex, and its haploinsufﬁciency was considered to contribute
to the DGS phenotype through dysregulating miRNA biogenesis.24
Sequence variants in the DGCR14 (DGSI) gene encoding a
component of C complex spliceosomes has been identiﬁed in
patients who had no detectable 22q11.2 deletion but had some of
the clinical features of DGS.25
Conotruncal heart defects are often observed without the other
characteristic symptoms of DGS as a sole abnormality, and in
around 10% of these patients, typical deletions within the
DiGeorge critical region could be detected,26–30 suggesting the
syndrome-causing roles of misregulated genes located within
the critical region, such as TBX1, in the observed conotruncal heart
defects. In other words, most of the patients with the typical
cardiac phenotype of conotruncal heart defects alone showed no
deletion of 22q11.2, as determined by FISH, leading to a
hypothesis that other genes could possibly be involved in the
cardiac malformation.
In this study, we investigated the presence of genomic
aberrations at the 22q11.2 region in six non-related patients with
conotruncal congenital heart defects, such as tetralogy of Fallot,
pulmonary atresia and truncus arteriosus. In all cases, deletions of
the 22q11.2 region could not be detected by FISH analysis using a
TUPLE1 probe nor was any mutation found in the TBX1 gene, the
key gene responsible for the phenotype of DGS. However, high-
resolution array comparative genomic hybridization detected
changes in copy number at the proximal end of the DiGeorge
critical region in two patients, indicating that gene(s) other than
TBX1 might also be responsible for the conotruncal heart defect
phenotype.
MATERIALS AND METHODS
Patients
Six unrelated patients with typical cardiovascular phenotype of DGS/velo-
cardio-facial syndrome such as tetralogy of Fallot, pulmonary atresia,
ventricular septal defect and truncus arteriosus in whom 22q11.2 deletion
was not detected by FISH analysis using TUPLE1 probe were included in
this study. Major features associated with the DGS such as thymic
hypoplasia, cleft palate and hypocalcemia were not observed in these
cases. The detailed information of the patients is presented in Table 1.
According to the Declaration of Helsinki, written informed consent was
obtained from the parents of all patients participating in this study. The
study was approved by the ethical committees of Ehime University and
The University of Tokushima. The molecular and molecular cytogenetic
analyses were performed using genomic DNA extracted from peripheral
blood mononuclear cells.
Fluorescence in situ hybridization (FISH)
FISH analysis of peripheral blood samples was performed using a Vysis
DiGeorge region probe (LSI TUPLE1 SpectrumOrange/LSI ARSA Spectrum-
Green probe, Abbott Laboratories, Abbott Park, IL, USA) to detect the
presence of 22q11.2 deletion, according to the manufacturer’s instructions.
DNA extraction
Mononuclear cells of the peripheral blood were separated by Ficoll-Paque
density centrifugation (GE Healthcare, Piscataway, NJ, USA), according to
the manufacturer’s instructions, and DNA was extracted from the
mononuclear cells by using standard procedures.
PCR and sequence analysis
PCR was performed with AmpliTaq Gold 360 Master Mix (Applied
Biosystems, Foster City, CA, USA) and Tks Gﬂex DNA Polymerase (Takara,
Otsu, Japan) at conditions recommended by the supplier. The obtained
PCR product was analyzed by electrophoresis and puriﬁed using the
QIAquick Gel Extraction Kit (Qiagen, Valencia, CA, USA). Direct sequencing
of puriﬁed PCR products was performed with a BigDye Terminator v3.1
Cycle Sequencing Kit (Applied Biosystems) on an automated ABI310
Genetic Analyzer (Applied Biosystems).
Multiplex ligation-dependent probe ampliﬁcation
SALSA MLPA Congenital Heart Disease probemix (P311, MRC-Holland,
Amsterdam, The Netherlands), which included three genes (CDC45L, GP1BB
and DGCR8) located on chromosome 22q11 within the 3-Mb commonly
deleted region, as well as other genes reported to be involved in
cardiogenesis, was used for analysis, following the manufacturer’s
instructions. All runs included DNA from three normal controls to calibrate
unknown samples. The reaction products were analyzed with an ABI310
Genetic Analyzer, and Coffalyser software (MRC-Holland) was used for copy
number analysis.
TaqMan copy number assays for TBX1
The presence of any copy number alterations of the TBX1 gene was
evaluated by quantitative PCR with TaqMan copy number assays (Applied
Biosystems) covering exon 2 (assay ID, Hs02267325_cn), exon 7
(Hs00856599_cn) and exon 10 (Hs01313390_cn) of the TBX1 gene. TaqMan
Copy Number Reference Assay for RNase P or TERT (Applied Biosystems)
was used as an internal reference for copy number analysis.
Array-based copy number analysis
Copy number analysis was performed using a genome-wide high-
resolution Affymetrix CytoScan HD array (Affymetrix, Santa Clara,
CA, USA) containing 42.6 million copy number markers, including
Table 1. Clinical features of the patients analyzed
Case Age Sex Cardiac defect Other symptoms
1 6y F TOF, PA, RAA, MAPCA —
2 2y M VSD, PA, RAA, Truncus —
3 4y F TOF Abnormal face
4 36y F TOF, PA —
5 29y M TOF —
6 4y M TOF, PA —
Abbreviations: F, female; M, male; MAPCA, multiple aortopulmonary
collateral arteries; PA, pulmonary atresia; PS, pulmonary stenosis; RAA,
right aortic arch; TOF, tetralogy of Fallot; Truncus, truncus arteriosus; VSD,
ventricular septal defect; y, year.
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approximately 750 000 single nucleotide polymorphisms, according to the
manufacturer's protocols. After scanning hybridized arrays, CEL ﬁles were
generated from Affymetrix GeneChip Command Console Software 4.1.2
(AGCC, Affymetrix) and imported into Chromosome Analysis Suite (ChAS)
Software v.2.1 to generate and visualize copy number, loss of hetero-
zygosity and genotyping data. For copy number analysis, ﬁve consecutive
markers with the same polarity were required for the minimum number of
markers per region, but no minimum size was set as the reporting
threshold for each region in order to detect small aberrations. For the
interpretation of the results, database of genomic variants (http://projects.
tcag.ca/variation/), DECIPHER database (https://decipher.sanger.ac.uk/),
Online Mendelian Inheritance in Man (http://www.omim.org), UCSC
(http://genome.ucsc.edu/, hg19) and the International Standards for
Cytogenomic Arrays (https://www.iscaconsortium.org/) were employed.
Quantitative PCR
Quantitative real-time PCR was performed using SYBR Premix ExTaq II
(Takara) and Universal SYBR Select Master Mix (Applied Biosystems) on a
StepOnePlus Real-Time PCR System (Applied Biosystems) with the PCR
conditions recommended by the supplier. All measurements were
performed in duplicate, and the difference in the duplicate threshold
cycle was less than one cycle in all samples tested. All experiments were
repeated at least three times. The primers used for real-time PCR are
summarized in Table 2.
RESULTS
No abnormalities were detected in the TBX1 gene in six patients
with conotruncal heart anomaly
Among the genes within the commonly deleted DiGeorge critical
region, TBX1 is the most probable candidate for causing the
phenotype observed in DGS. As mutations in the TBX1 gene have
been shown to be responsible for the phenotype in DGS/
velo-cardio-facial syndrome patients without detectable 22q11.2
deletion, the presence of any mutation in this gene was examined
by direct sequencing, using genomic DNA extracted from
peripheral blood mononuclear cells of the patients. In all the six
patients enrolled in this study, no mutation was detected in the
coding regions of the TBX1 gene (exons 1 to 8, 9A, 9B, 9C and 10)
and in the surrounding exon–intron junction. In addition, copy
number assessment of exons 2, 7 and 10 by quantitative real-time
PCR analysis (TaqMan Copy number assay) showed neither
deletion nor ampliﬁcation of these exons in all the patients
examined (data not shown). Moreover, there were no copy
number alterations in the genes associated with cardiogenesis in
all the patients analyzed using SALSA MLPA Congenital Heart
Disease probemix.
Microdeletion and duplication were detected at the proximal part
of the DiGeorge critical region in two patients
Copy number variation (CNV) analysis on a genomic scale was
performed using the Affymetrix CytoScan HD array in all patients.
In the six patients, 1036 CNVs (211 gains and 825 losses) were
observed, indicating 172.7 CNVs per individual analyzed (35.2
gains and 137.5 losses). In two out of the six patients, copy
number alterations were detected in the proximal side of the
DiGeorge critical region, although results obtained by array-based
analysis left some uncertainty regarding the genomic breakpoint/
borderline of copy number alteration on the 22q11.2 region owing
to scarcity of probes located around the region (Figure 1). One
patient (case 1) showed a monoallelic deletion, spanning
approximately 108.0–375.6 kb, and the other (case 2) showed a
duplication, spanning approximately 87.9–375.6 kb around this
region (Figure 1). The other four patients showed no copy number
alteration within the DiGeorge critical region. In addition, no other
copy number alteration that is likely to be responsible for the
phenotypes was detected in any of the six patients. Consents for
Table 2. Primer sequences used in the study
Regiona Gene Name Sequence
PGK2 PGK2–392f 5′-CTGTTGCTGTTGAGCTCAAATCC-3′
PGK2–445r 5′-CCACTTCTGCGCCTACACAGTC-3′
B2M b2MG-142f 5′-CAGGTTTACTCACGTCATCCAG-3′
b2MG-194r 5′-GGATGAAACCCAGACACATAGC-3′
HPRT1 HPRT1–305f 5′-TGAACGTCTTGCTCGAGATGTG-3′
HPRT1–344r 5′-ACAGAGGGCTACAATGTGATGG-3′
1 TUBA8 TUBA8-g39100f 5′-GAACATGTGCCCTGTGAAGTGC-3′
TUBA8-g39145r 5′-AAATGAGGCAGTCGGTGACCAC-3′
2 USP18g-11849f 5′-AGATGGTCCATCACTTACCGTG-3′
USP18g-11898r 5′-GTCAAGTCCCAGTGAACCCATC-3′
3 USP18 USP18g-26519f 5′-ACTCGGAGCACCTGTTGACCC-3′
USP18g-26569r 5′-TAATCTCCTGAGGGCCGCTAAC-3′
4 USP18g-41603f(m) 5′-GAATGCGTGGGCTTTATGTGAAGA-3′
USP18g-41733r(m) 5′-GTGGGAACTCTGGAAGTCCTTC-3′
5 TMEM191B-5up 1F(m) 5′-CACCAAGGAACCTACTTCAAGGA-3′
TMEM191B-5up 1R(m) 5′-CACCACCTAGGCTGGCCTGT-3′
6 DGCR6g-10000f 5′-CTGGGTGCAGCCTGATGTTCTG-3′
DGCR6g-10094r 5′-AGAGAAACAGCTCTGCCGTGAGA-3′
7 DGCR6g-12568f 5′-GCCAGGTGTACAGGATGACTAGG-3′
DGCR6g-12621r 5′-TCCCTGTGATGCTGTGCTTCAG-3′
8 DGCR6 (intron 3) DGCR6g-18001f 5′-GTGCTCCCCTGGAGTCCATTAG-3′
DGCR6g-18077r 5′-GCCCCATCACCCCACCATTGC-3′
9 PRODH (exon 15) PRODH-1837f 5′-GTGTACAAGTACGTGCCCTATGG-3′
PRODH-1900r 5′-TCATGAGGCTGCTGTTCTCCAG-3′
10 PRODH (exon 1) PRODH-90f 5′-TCCCCACCATGCAGCTGAAGTG-3′
PRODH-136r 5′-TTCCTGACAAATGCCAGACAAGG-3′
11 DGCR9 DGCR9–29f 5′-CTCAAAGAGCCAAAGTCATCCTC-3′
DGCR9–120r 5′-CCATGCTGTTTTGGTTACCATGC-3′
12 DGCR2 (exon 10) DGCR2–1645f 5′-ACGATGATGCTTTTGAGCCTGTG-3′
DGCR2–1700r 5′-CCGGAGTAATGCACCTTCACTC-3′
aRegion numbers correspond to the numbers of Figure 1b indicating the approximate sites of the primer pairs.
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blood sampling from the parents to determine the origin of these
copy number alterations could not be obtained.
The affected region contains the DGCR6 and PRODH genes
Within the proximal side of the DiGeorge critical region, showing
copy number alterations in two patients, there are several genes,
including USP18 at the proximal end and DGCR6 and PRODH at the
distal end. Copy number alterations of these genes were analyzed
by quantitative real-time PCR analysis. In case 1, the genomic area,
including the PRODH, DGCR6, DGCR5 and DGCR9 genes was
deleted, resulting in only one remaining allele of these genes,
whereas both alleles of DGCR2 seemed to be retained. In case 2,
the same genomic area that was lost in case 1 was duplicated
instead, including PRODH and DGCR6 to DGCR9 genes (Figure 2).
In addition, small isolated copy number alteration at the 3’
downstream region of the USP18 gene was detected in case 2 by
quantitative PCR analysis, which was not observed in any other
patient or control samples. Regardless of this observation, coding
regions of the DGCR2 and USP18 genes at the distal and proximal
end of the altered region remained intact in both cases. As array
comparative genomic hybridization probes are usually not located
in the region containing DGCR6 gene, and because public
database data concerning the copy number changes of the
region in healthy individuals may be restricted, we analyzed the
gene dosage of DGCR6 in 50 control samples by quantitative PCR.
There was no CNV of the gene in all individuals analyzed (data not
shown). This indicated that copy number alteration of the DGCR6
gene is not a common event in healthy individuals, and that copy
number changes of the gene observed in two out of the six
patients with conotruncal heart defects could be one of the
disease-causing variations.
DISCUSSION
A characteristic cardiac anomaly is one of the hallmarks of DGS,
observed in approximately 80% of the patients,1–3 and its rather
speciﬁc morphology often leads to the diagnosis of DGS. Although
the deletion within the 22q11.2 region is observed in about
10% of patients with stand-alone conotruncal heart defects
lacking any other symptoms of DGS, most of the patients with
these stand-alone conotruncal heart defects show no abnormality
when evaluated by the standard FISH screening for 22q11.2
deletion.26–30
Two out of six cases presented in this report have atypical small
deletion/duplication at the proximal end of the commonly deleted
region in DGS. Both copy number analysis by high-resolution array
and mutation analysis failed to detect any abnormalities within
the TBX1 gene in these patients. In both cases, copy number
alterations resided in the so-called LCR-A region, which is located
at the proximal end of the commonly deleted region in DGS.
Detailed copy number analysis by quantitative real-time PCR
suggested that this small deletion/duplication region involves four
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Figure 1. Microdeletion and duplication at the proximal part of the DiGeorge syndrome critical region detected in two patients by high-
resolution array and quantitative PCR analysis. (a) Result of high-resolution array analysis in two cases. A small deletion, including at least
DGCR9, DGCR5 and PRODH, was observed in case 1, whereas almost the same region was duplicated in case 2. The area without any dots is
where the array probe does not exist. The light and the dark brown bars show the estimated maximum and minimum deleted area in case 1,
respectively. The light and dark purple bars show the estimated maximum and minimum duplicated area in case 2, respectively. (b) Genes
located in this area are presented. The arrows indicate the locations of primers used in quantitative PCR analysis shown in Figure 2.
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genes at the proximal end of the DiGeorge critical region: DGCR6,
PRODH, DGCR5 and DGCR9. The products of DGCR5 and DGCR9 are
non-coding RNA with unknown signiﬁcance, whereas the other
two genes, DGCR6 and PRODH, encode proteins with several
functions.23,31,32 These two genes reside close together on
22q11.2 region, with a distance of about 0.7 kb between their
respective tail positions.
Although many studies have concluded that the phenotype
does not correlate to the length of the deletion in the 22q11.2
region, a few studies indicated that some phenotype–genotype
correlation could be observed by detailed analysis.11 In patients
with aberrant cardiac morphology, although the length and
breakpoints of the deleted regions on 22q11.2 varied, the
presence of conotruncal heart defects was almost always
accompanied by a large deletion measuring 3 or 1.5 Mb in length,
involving the TBX1 gene region.11 Patients with deletions distal to
these commonly deleted regions showed rather atypical heart
defects.11
Although only a few reports describing the actual mapping of
the proximal breakpoints in DGS are available,33,34 proximal
breakpoints were usually located around the region that contains
the DGCR6 and PRODH genes, which exactly corresponds to the
affected regions in the two cases reported here. The more
proximally located genes USP18 and TUBA8 were both often
retained in patients with typical 3 Mb or nested 1.5 Mb proximal
22q11.2 deletions, as observed in the two patients analyzed in
this study.
Figure 3 presents the location of copy number alterations
reported in cases that have a small deletion or duplication
proximal to the DiGeorge critical region. In all the six cases
evaluated, DGCR6 and PRODH are included or suspected to be
included in the altered fragment, and they all show a heart defect
that is observed in DGS. These reports also support our notion that
DGCR6 may also be responsible for the heart anomaly observed
in DGS.
DGCR6 is located most centromeric within the DGS critical
region.35 The DGCR6 protein is a nuclear phosphoprotein highly
expressed in the heart, liver and skeletal muscle.31 During murine
embryogenesis, Dgcr6 shows widespread distribution, with the
highest expression being observed in the pharyngeal arches, the
central and peripheral nervous systems, and cardiac ganglion
cells.36 In a chicken model, DGCR6 suppression in neural crest cells
by retrovirus-mediated antisense transduction resulted in a high
incidence of severe cardiovascular anomalies reminiscent of those
found in DGS, possibly through the modulation of the expression
level of some of the genes located within the DiGeorge critical
region, including TBX1.23
PRODH encodes for proline dehydrogenase, a mitochondrial
rate-limiting enzyme in the proline degradation process. Homo-
zygous mutations in the PRODH gene lead to hyperprolinemia
type I, a rare neurologic disorder with variable manifestations such
as seizures, mental retardation, and psychiatric and behavioral
disorders. Although multiple studies in human and mouse models
indicate that abnormalities of PRODH are associated with the risk
of psychiatric disorders,37–39 no positive relationship between
congenital heart defects and aberrant PRODH gene copy number
was reported prior to this study. Collectively, these observations,
in conjunction with the roles of DGCR6 and PRODH described in
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Figure 2. Identiﬁcation of genes within microdeletion and duplication areas at the proximal part of the DiGeorge critical region, as conﬁrmed
by quantitative PCR analysis. (a) The affected regions in cases 1 and 2 contain DGCR6, PRODH and DGCR9 genes, as conﬁrmed by quantitative
PCR. PGK2 was used as an internal reference, and the average value of six control DNA samples was set as one for each primer set. Case 2 is a
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the literature, strongly indicate that DGCR6, not PRODH, might be
involved in the pathogenesis of conotruncal heart defects by
some yet unknown mechanisms, although the roles of non-coding
RNAs such as DGCR5 and DGCR9 that also reside in the affected
region cannot be completely excluded.
Though interstitial deletions are the most common genomic
variation associated with DGS by far,40,41 other genomic
instabilities that disrupt chromosome 22q11.2 have been reported
in patients with a phenotype similar to that of DGS. In particular,
individuals carrying microduplications mediated by the LCRs have
also been reported.42 The phenotype of patients with 22q11.2
microduplications is extremely variable, ranging from multiple
defects to mild learning difﬁculties, and shares some features of
DGS such as velopharyngeal insufﬁciency, urogenital abnormal-
ities and conotruncal heart defects.43 In addition, a gain-of-
function mutation of TBX1 was also identiﬁed in some patients
with the phenotype of DGS.44 In a BAC transgenic mouse model,
heterozygous deletion of the TBX1 gene region and duplication of
the region containing TBX1 showed development of conotruncal
heart defects as observed in DGS.45,46 These observations indicate
that whether deleted or duplicated, a change in the gene dosage
in any of the causative genes may contribute to the phenotype of
22q11.2 syndrome such as conotruncal heart defects. Although a
detailed mechanism is still unknown, Liao et al.46 suggested a
model for TBX1 dosage effects by hypothesizing that TBX1 acts as
heterodimer for transcriptional regulation of its target genes. Both
reduction and increase of the amount of TBX1 protein hinders
appropriate heterodimer formation with its partner and target
DNA binding, resulting in a loss/reduction of transcriptional
regulation. The same explanation may apply to DGCR6, which is
also a transcriptional regulator related to TBX1.
CNVs of DGCR6 were only identiﬁed in two patients out of the
six analyzed in our study. There may be two explanations for this.
One possibility is that some genetic changes that have signiﬁcant
impact on expression or function of the DGCR6 gene are present
within the region but could not be detected by array comparative
genomic hybridization (for example, very small copy number
change(s) or some genetic alteration in promoter or enhancer of
DGCR6). The other possibility is that there is a genetic alteration in
some other gene(s) that is responsible for the phenotype. In this
regard, we have undergone mutational analysis of possible
candidate genes, such as FGF8, CRKL, MAPK1 and HIC2
genes.14,17–19 We could not detect any genetic variation in the
coding region of these genes in all six cases analyzed in this study.
Further analysis is necessary to identify the responsible genetic
abnormalities in these four cases.
In summary, the six patients analyzed in this study have typical
conotruncal heart defects that are frequently observed in DGS.
However, we have failed to identify any abnormalities in the TBX1
gene in any of the six patients. Instead, small genomic copy
number alterations that involve the DGCR6 and PRODH genes
were identiﬁed in two patients. Although one presented deletion,
while the other showed duplication, these two genes may be
responsible in the pathogenesis of conotruncal heart defects in
these patients by some common mechanism. As the altered
expression of DGCR6 was previously reported to be a cause of the
cardiac malformation observed in a chicken model of DGS,23 the
ﬁndings of our study further support the pathological role of
DGCR6 in conotruncal heart defects. Further analysis of more
cases and a possible functional relationship between DGCR6 and
TBX1 during cardiogenesis is necessary to clarify the role of DGCR6
in conotruncal heart defects.
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Figure 3. Reported cases with copy number alteration in the proximal part of the DiGeorge critical region. The bars with case numbers show
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Red bars indicate deleted regions, and blue bars indicate duplicated regions. Light and dark red bars show the estimated maximum and
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